Laddar...
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
We present response and survival outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant (N = 102) after a median observation period of approximately 3 years. Median overall...
Sparad:
| I publikationen: | Blood |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
American Society of Hematology
2015
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4335079/ https://ncbi.nlm.nih.gov/pubmed/25533035 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-08-595801 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|